Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1386, 2003-01, pp. : 5-5
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
IFN- -2b + ribavirin preferred initial treatment for hep C
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 274, 2000-01 ,pp. :
Access to resources
Recommend
IFN- -2b + ribavirin preferred initial treatment for hep C
Inpharma, Vol. 1, Iss. 1249, 2000-01 ,pp. :
PEG IFN- -2b plus ribavirin worth its cost in chronic hepatitis C
Inpharma, Vol. 1, Iss. 1379, 2003-01 ,pp. :
Weight-based ribavirin eases the load of hepatitis C
Inpharma, Vol. 1, Iss. 1522, 2006-01 ,pp. :
Evaluating EVR to PEG IFN-α-2b/ribavirin therapy worthwhile
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 491, 2005-01 ,pp. :